Xbrane Biopharma AB (publ) (STO:XBRANE)

Market Cap	316.86M
Revenue (ttm)	198.72M
Net Income (ttm)	-266.22M
Shares Out	1.53B
EPS (ttm)	-0.22
PE Ratio	n/a
Forward PE	1.56
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,814,336
Average Volume	31,015,622
Open	0.2072
Previous Close	0.2068
Day's Range	0.1985 - 0.2082
52-Week Range	0.1262 - 0.3725
Beta	0.98
RSI	56.02
Earnings Date	Mar 31, 2025

About Xbrane Biopharma AB

Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. Its pre-clinical phase products include BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriati...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 65
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: XBRANE

Financial Performance

In 2024, Xbrane Biopharma AB's revenue was 198.72 million, a decrease of -16.76% compared to the previous year's 238.73 million. Losses were -266.22 million, -31.42% less than in 2023.